<DOC>
	<DOCNO>NCT01558492</DOCNO>
	<brief_summary>The purpose study look clinical benefit carboplatin paclitaxel correlate response study treatment biologic parameter ( i.e . lab study blood , urine , tissue ) . It hop allow researcher gain insight underlie biology prostate tumor progression perhaps predict patient may benefit chemotherapy regimen .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Patients With Metastatic , Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>Docetaxel/prednisone standard care patient metastatic , castrate-resistant prostate cancer ( CRPC ) duration response limit , median time prostate-specific antigen ( PSA ) progression 6-8 month . There currently standard second-line therapy patient progress receive docetaxel . Carboplatin paclitaxel demonstrate activity , prospective clinical trial evaluate regimen limit . In addition , correlative study investigate patient respond lacking .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologic cytologic diagnosis prostate carcinoma . Subject must progressive metastatic prostate cancer despite adequate medical surgical castration therapy . Furthermore , applicable , medical castration must maintain duration protocol . Serum testosterone &lt; 50 ng/ml . Subjects receive antiandrogen therapy result PSA decline must demonstrate progression follow discontinuation antiandrogen therapy . Subjects capable fathering child must agree use effective method contraception duration trial . Must previously receive docetaxel prostate cancer ECOG performance status 02 Willing able give inform consent Platelet count &lt; 100,000/mm3 Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 Hemoglobin &lt; 8 g/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal Bilirubin ( total ) &gt; 2 x upper limit normal . Subjects know Gilbert 's syndrome eligible direct bilirubin within normal limit For subject serum creatinine &gt; 1.5 x ULN , calculate creatinine clearance &lt; 30 ml/min exclude ; subject meet exclusion criterion eligible measure clearance &gt; 30 ml/min Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study Prior investigational therapy within 4 week treatment . Furthermore , investigational anticancer therapy permit treatment phase . Grade &gt; 1 peripheral neuropathy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic Castrate Resistant Prostate Cancer</keyword>
	<keyword>CRPC</keyword>
</DOC>